Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vivos Therapeutics, Inc. (VVOS : NSDQ)

• Company Description    Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado. Number of Employees: 268

• Price / Volume Information    Yesterday's Closing Price: $0.61 Daily Weekly Monthly 20 Day Moving Average: 174,599 shares Shares Outstanding: 13.90 (millions) Market Capitalization: $8.48 (millions) Beta: 6.25 52 Week High: $7.95 52 Week Low: $0.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.91% -35.24% 12 Week -57.93% -61.11% Year To Date -69.95% -73.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7921 SOUTHPARK PLAZA SUITE 210 - LITTLETON,CO 80120 USA ph: 866-908-4867 fax: - investors@vivoslife.com http://www.vivos.com

• General Corporate Information    Officers R. Kirk Huntsman - Chairman of the Board and Chief Executive Officer Bradford Amman - Chief Financial Officer Anja Krammer - Director Mark F. Lindsay - Director Gregg C. E. Johnson - Director Peer Information Vivos Therapeutics, Inc. (GSAC) Vivos Therapeutics, Inc. (CASIF) Vivos Therapeutics, Inc. (ALCD.) Vivos Therapeutics, Inc. (OMNN) Vivos Therapeutics, Inc. (CGPI.) Vivos Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 92859E207 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/18/26 Share - Related Items Shares Outstanding: 13.90 Most Recent Split Date: 10.00 (0.04:1) Beta: 6.25 Market Capitalization: $8.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/18/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.43 EPS Growth vs. Year Ago Period: -15.56% vs. Previous Quarter: 10.34% Sales Growth vs. Year Ago Period: 70.46% vs. Previous Quarter: 34.44% ROE 03/31/26 - -2,325.64 12/31/25 - -849.22 09/30/25 - -351.28 ROA 03/31/26 - -98.12 12/31/25 - -96.11 09/30/25 - -87.44 Current Ratio 03/31/26 - 0.27 12/31/25 - 0.24 09/30/25 - 0.78 Quick Ratio 03/31/26 - - 12/31/25 - 0.24 09/30/25 - 0.78 Operating Margin 03/31/26 - -127.70 12/31/25 - -121.37 09/30/25 - -98.77 Net Margin 03/31/26 - -127.70 12/31/25 - -121.37 09/30/25 - -98.77 Pre-Tax Margin 03/31/26 - -128.36 12/31/25 - -121.71 09/30/25 - -98.77 Book Value 03/31/26 - -0.09 12/31/25 - -0.16 09/30/25 - 0.34 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - 3.31 Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - 76.79

Powered by Zacks Investment Research ©